IAMA 003
Alternative Names: IAMA-003Latest Information Update: 26 Sep 2024
At a glance
- Originator Nanjing JSIAMA Biopharmaceuticals
- Class Antibodies; Drug conjugates; Immunoconjugates; Oligonucleotides
- Mechanism of Action Gene silencing; Protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 09 Sep 2024 Early research in Unspecified in China (Parenteral) prior to September 2024 (Nanjing JSIAMA Biopharmaceuticals pipeline, September 2024)